Drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT02856425
First seen Jan 22, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (an anti-angiogenesis drug)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nintedanib when given with pembrolizumab. The study aimed to see if this combination could be better tolerated and more effective than either drug alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ANY ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Gustave Roussy
Villejuif, Val De Marne, 94805, France
-
Hôpital Bichat
Paris, 75018, France
-
IUCT--O
Toulouse, 31059, France
-
Institut Bergonié
Bordeaux, 33000, France
Conditions
Explore the condition pages connected to this study.